CN105597098A - Trastuzumab bond-linking gold nanorod compound, preparation method and application thereof in diagnosis and treatment of HER2 positive breast cancer - Google Patents
Trastuzumab bond-linking gold nanorod compound, preparation method and application thereof in diagnosis and treatment of HER2 positive breast cancer Download PDFInfo
- Publication number
- CN105597098A CN105597098A CN201511003574.5A CN201511003574A CN105597098A CN 105597098 A CN105597098 A CN 105597098A CN 201511003574 A CN201511003574 A CN 201511003574A CN 105597098 A CN105597098 A CN 105597098A
- Authority
- CN
- China
- Prior art keywords
- solution
- gold nanorods
- porphyrin
- compound
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 gold nanorod compound Chemical class 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 238000003745 diagnosis Methods 0.000 title claims abstract description 11
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 title abstract description 7
- 229960000575 trastuzumab Drugs 0.000 title abstract 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 72
- 229910052737 gold Inorganic materials 0.000 claims abstract description 32
- 239000010931 gold Substances 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 19
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000018417 cysteine Nutrition 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- 239000002073 nanorod Substances 0.000 claims abstract description 4
- 229940022353 herceptin Drugs 0.000 claims description 42
- 230000027455 binding Effects 0.000 claims description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 13
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 13
- 150000004032 porphyrins Chemical class 0.000 claims description 13
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- SJUCACGNNJFHLB-UHFFFAOYSA-N O=C1N[ClH](=O)NC2=C1NC(=O)N2 Chemical compound O=C1N[ClH](=O)NC2=C1NC(=O)N2 SJUCACGNNJFHLB-UHFFFAOYSA-N 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 235000007164 Oryza sativa Nutrition 0.000 claims description 5
- 235000009566 rice Nutrition 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- KZBCIIQGKQUYBD-UHFFFAOYSA-N ClCCOC1=C(C=C(C=C2)N=C2C=C(C=C2)NC2=CC(C=C2)=NC2=C2)NC2=C1C1=CC=CC=C1 Chemical compound ClCCOC1=C(C=C(C=C2)N=C2C=C(C=C2)NC2=CC(C=C2)=NC2=C2)NC2=C1C1=CC=CC=C1 KZBCIIQGKQUYBD-UHFFFAOYSA-N 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QCWPXJXDPFRUGF-UHFFFAOYSA-N N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 Chemical compound N1C=2C=C(N=3)C=CC=3C=C(N3)C=CC3=CC(=N3)C=CC3=CC1=CC=2C1=CC=CC=C1 QCWPXJXDPFRUGF-UHFFFAOYSA-N 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 239000013049 sediment Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 238000007626 photothermal therapy Methods 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 238000010382 chemical cross-linking Methods 0.000 abstract description 2
- 230000003287 optical effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000001394 metastastic effect Effects 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241000209094 Oryza Species 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000000015 thermotherapy Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000972286 Homo sapiens Mucin-4 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002078 nanoshell Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a trastuzumab bond-linking gold nanorod compound, a preparation method and application thereof in the diagnosis and treatment of HER2 positive breast cancer, which overcome the defects of poor regulation of photo-thermal conversion efficiency and incapability of location of targeting gold nanoparticles. The preparation method comprises the following steps: firstly, preparing a gold nanorod with a certain length-diameter ratio, wherein the longitudinal absorption peak is 650 to 850nm, and the nanorod is capable of meeting the optimal optical wavelength penetrating through tissue of a human body; then connecting cysteine with porphyrinfluorescent molecules, next, through the action of an Au-S bond, bond-linking the gold nanorod with a cysteine-porphyrin compound, finally through a glutaraldehyde chemical crosslinking method, bond-linking a gold nanorod-cysteine-porphyrin compound with a drug trastuzumab. The obtained trastuzumab bond-linking gold nanorod compound is capable of showing in-situ or micro metastatic focus, and performing a targeting photo-thermal therapy on a detected tumor focus, so that the difficult problem of drug resistance of tumor can be effectively solved.
Description
Technical field
The present invention relates to a kind of Herceptin binding gold nanorods compound, also relate to the system of this nanometer rods compoundPreparation Method and applying in the diagnosis and treatment of HER-2 positive breast cancer, the invention belongs to biological medicine technology field.
Background technology
Along with clinical development and the application of new drug and new method, the result for the treatment of of early-stage breast cancer has had very large proposingHeight, but 5 years survival rates of three phases and fourth phase breast cancer still only have 57% and 20%, wherein epidermal growth factorPatient with breast cancer's relapse and metastasis risk of son 2 acceptors (HER2) positive expression is very high, and prognosis is especially poor. 2006Year, Roche Holding Ag of Switzerland developed first molecular targeted agents---the song for breast cancer cell HER2 target spotTrastuzumab, it can be combined with HER2, and the relevant tumor growth signal path of blocking-up HER2, suppresses HER2The propagation of the tumour cell of overexpression. Herceptin is used for each phase HER2 positive by FDA approval at presentThe treatment of breast cancer, but there is primary drug resistance in some patients, also have many trouble in the time starting Herceptin treatmentPerson treats in latter 1 year and in succession occurs resistance accepting Herceptin. How overcoming this treatment bottleneck is breast cancerThe a great problem that treatment faces.
Herceptin resistance is relevant to much mechanism, comprises that glycoprotein MUC4 crosses expression, insulin-like growth factorSon is crossed and is expressed and intrinsic P13K/Akt activity etc., very rare as for the situation of HER2 acceptor extracellular region mutation,In most of the cases HER2 acceptor itself unchanged is controlled these multiple factors relevant to resistance non-simultaneouslyNormal difficulty, so we have expected carrying out thermotherapy taking Herceptin as carrier is accurately targeted to lesions position, passes throughPhoto-thermal therapy kills remaining drug-resistant tumor cell.
In numerous nano materials that can be applicable to biomedical aspect, gold nano family has good bio-compatibleProperty and easily by modify characteristic, therefore in the Clinics and Practices of tumour, have good application prospect, and obtained someThere is the achievement in research of actual application value. For example, the golden nanometer particle of EGFR antibody modification is for the morning of tumourPhase diagnosis, can significantly distinguish tumour cell and normal cell. The people such as YangJ by EGFR specific antibody-Cetuximab Cetuximab is connected on golden nanometer particle, utilizes the optical characteristics of golden nanometer particle to pass through opticsImage obtains so that HCC is different from normal cell. The people such as MukherjeeP study discovery, and golden nanometer particle canWith specifically, in conjunction with VEGF-165 and bFGF, performance suppresses the effect that tumor vessel generates; AgastiSS etc.People is connected in 5-FU by O-nitrobenzyl (O-nitrobenzyl, ONB) surface of golden nanometer particle, developmentA kind of golden nanometer particle-antineoplastic controlled release system of " light reaction " property.
On the basis of these domestic and international early-stage Study, the present invention is in conjunction with specific target tropism and the Jenner of HerceptinThe application characteristic of rice corpuscles in oncotherapy, will prepare the gold nano being connected by Herceptin key by chemical synthesisParticle. But tumor thermotherapy is a complicated process, due to the light of the different wave length penetration capacity difference to tissue,Its thermal efficiency of light that tissue penetration ability is strengthened just reduces, and the not enough accurate focus portion that just cannot arrive of penetration powerPosition. Due to the radiai adjustment scope of conventional gold nanoshell single (only have the radius of a ball adjustable), cannot meet treatmentThe demand of different depth tumour in different big or small tumours and body, gold nanorods key is connected Herceptin by we, simultaneouslyBefore in conjunction with Herceptin, connect gold nanorods by cysteine-porphyrin key, utilize the video picture of porphyrin near-infrared fluorescent to knowOther tumor focus position, the effect of arrival image location and targeting thermotherapy.
Summary of the invention
It is appropriate that technical problem to be solved by this invention is to provide the song of a kind of HER2 of can be used in positive breast cancer diagnosis and treatmentPearl monoclonal antibody binding gold nanorods compound and preparation method and purposes.
In order to achieve the above object, the present invention has adopted following technological means:
(1) prepare the gold nanorods that draw ratio is different, longitudinally absworption peak is 650-850nm, can meet and penetrateThe optimal light wavelength of tissue, and under a small amount of CTAB parcel stable existence;
(2) prepare the porphyrin fluorescence molecule of the cysteine of binding varying number, thereby may effectively controlThe amount of binding Herceptin on gold nanorods;
(3) by the method for glutaraldehyde chemical crosslinking, by gold nanorods-cysteine-porphyrin compound and medicine songTrastuzumab key connects, and the gold nanorods-cysteine-porphyrin-Herceptin compound obtaining, can disperse wellIn DMF solution.
A kind of Herceptin binding gold nanorods compound of the present invention, it is by the effect of Au-S key, willGold nanorods and cysteine-porphyrin fluorescence molecule compound key connect, then by the side of glutaraldehyde chemical crosslinkingMethod, gets gold nanorods-cysteine-porphyrin fluorescence molecule compound and medicine Herceptin key continuously, itsThe each several part being connected by next coming in order forms: gold nanorods, cysteine, porphyrin fluorescence molecule and bent appropriate pearlMonoclonal antibody.
Wherein, preferred, described porphyrin fluorescence molecule is to chloroethoxy phenyl porphyrin.
A method of preparing above-described Herceptin binding gold nanorods compound, comprises the following steps:
1) preparation of gold nanorods
A. the preparation of gold seeds liquid: to the CTAB solution that adds 7.5ml0.1M in beaker, in gentle agitationUnder condition, add the chlorauric acid solution of 250 μ l0.01M, then add the boron hydrogen of the 0.01M of freshly prepared 0 DEG CChange sodium solution 60 μ l, at the temperature of 22-28 DEG C, gentle agitation 1-5min, stand-by;
B. the preparation of growth-promoting media: to the CTAB solution that adds successively following solution: 0.1M in another beaker10ml, the chlorauric acid solution 425 μ l of 0.01M, the liquor argenti nitratis ophthalmicus 60 μ l-100 μ l of 0.01M, 0.1M's is anti-badHematic acid solution 67 μ l, obtain growth-promoting media after mixing;
C. the preparation of gold nanorods: gold seeds liquid 105 μ l are joined in growth-promoting media, and whole process is all slightly being stirredMix and temperature is to carry out under the condition of 22-28 DEG C, continue to stir after adding medicine, after solution changes color, will burnIt is in the water bath with thermostatic control of 27-28 degree Celsius that cup moves into temperature, the static processing of spending the night; After having reacted, obtain gold nanorodsSolution, moves into gold nanorods solution in centrifuge tube, centrifugally front solution is carried out to heat treated, treats in solutionAfter CTAB all dissolves, by putting into centrifuge after medicine trim, centrifugal, centrifugal complete supernatant is inhaled with suction pipe afterwardsGo out, precipitate with deionized water is dissolved again, repeats above centrifugal process 2 times, and the gold nanorods of collection is resuspended inIn the deionized water of appropriate volume, the gold nanorods solution of collection is placed in the refrigerator of 4 DEG C and preserves, for afterSign and react again;
2) porphyrin gold nanorods key connects
D. the preparation of porphyrin-cysteine solution: in flask, add the DMF solution of 25ml, 50mg to chloroetheneOxygen base phenyl porphyrin, 0.75g-1.25g cysteine, after being uniformly mixed, adds 2～3 triethylamines, heatingReaction 24h, adds saturated aqueous common salt and carrene to carry out product separation, will be dissolved with the dichloromethane of target substanceAlkane is purified by column chromatography, obtains porphyrin-cysteine solution;
E. the preparation of gold nanorods-cysteine-porphyrin: add successively methyl alcohol in beaker, above-mentioned steps c obtainsGold nanorods solution and porphyrin-cysteine solution of obtaining of steps d, stirring at normal temperature 18-24h, after reaction finishesCentrifugal, outwell solution above, add methyl alcohol again centrifugal, outwell solution above, then add DMF to disperse heavyForm sediment, ultrasonic processing is dispersed in solution precipitation better, obtains gold nanorods-cysteine-porphyrin compound;
3) preparation of Herceptin binding gold nanorods compound
First gold nanorods-cysteine-porphyrin compound is dispersed in the CTAB solution of 0.005M, makes JennerThe concentration of rice rod-cysteine-porphyrin compound is 100nM, then uses glutaraldehyde cross-linking method, by the Jenner of 10mlRice rod-cysteine-porphyrin complex solution is dispersed in the PBS solution that concentration is 0.01M, and normal temperature is placed0.5-2h, centrifugal treating, precipitation is dispersed in the PBS solution of the 0.01M preparing again, and it is excessive then to addHerceptin, hatch 12h at 4 DEG C, centrifugally remove unnecessary Herceptin, obtain gold nanorods-half GuangPropylhomoserin-porphyrin-Herceptin compound, is dispersed in the compound obtaining in the PBS solution of 0.01M temperature4 DEG C of preservations, to obtain final product.
Wherein, preferred, the PBS solution of described 0.01M is for containing 1.38MNaCl, 0.0027MKCl,The PBS solution of the 0.01M of 0.05% (v/v) Tween-20 and 5% (v/v) glutaraldehyde, pH7.4.
Further, the invention allows for described Herceptin binding gold nanorods compound in preparationApplication in HER2 positive breast cancer diagnosis and treatment reagent.
Compared to prior art, beneficial effect of the present invention is:
The present invention has overcome shortcoming of the prior art, and a kind of tumor-targeting treatment gold nano that can video picture is providedRod, this gold nanorods has more superior performance, and it has the optics opposite sex main manifestations on horizontal and verticalFeature (transverse diameter and vertical footpath are all adjustable), on radical length, more than its wave-length coverage can be adjusted to 1400nm,Thereby tissue is had to better penetration capacity; In the horizontal, we can be adjusted to its resonant wavelengthBetween 600-800nm, this wave-length coverage is applicable to the photo-thermal therapy of tumour very much. Therefore we are single in conjunction with the appropriate pearl of songAnti-specific target tropism and application advantage and the porphyrin light of gold nanorods in oncotherapy to HER2 positive breast cancerThe sensitivity of dynamics diagnosis, prepares by Herceptin and porphyrin modified gold nanorods, profit by chemical synthesisSpecific target tropism with Herceptin to HER2 positive breast cancer, is targeted to disease by porphyrin and gold nanorods fixed pointKitchen range position, by the irradiation of suitable wavelength, utilizes the photodynamic reaction of porphyrin to position diagnosis to tumour, canWith the carcinoma in situ or the micrometastasis focus that detect that commonsense method is difficult to detect, utilize the distinctive light of gold nanorods simultaneouslyHot feature, carries out targeting photo-thermal therapy to the breast cancer focus detecting. This targeting thermotherapy is by physics sideMethod is destroyed the tumour cell of resistance, can effectively solve a difficult problem for molecular targeted agents resistance.
Brief description of the drawings
Fig. 1 is the synthetic gold nanorods porphyrin compound image under transmission electron microscope;
Fig. 2 is that the gold nanorods compound of different proportion porphyrin-cysteine is combined with HER2 high expression tumour cellFluorescent imaging;
Fig. 3 is the photo-thermal therapy effect of gold nanorods compound to BT474 cell;
Fig. 4 is gold nanorods compound target tumor focus imaging.
Detailed description of the invention
Further describe the present invention below in conjunction with specific embodiments and the drawings, advantage and disadvantage of the present invention will be withDescribe and more clear. But these embodiment are only exemplary, scope of the present invention are not formed to any limitSystem. It will be understood by those skilled in the art that can be to the present invention under without departing from the spirit and scope of the present inventionThe details of technical scheme and form are modified or are replaced, but these amendments and replacement all fall into protection model of the present inventionIn enclosing.
The preparation of embodiment 1 Herceptin binding gold nanorods compound
Embodiment of the present invention and step:
1) preparation of gold nanorods
A. the preparation of gold seeds liquid: to the CTAB solution that adds 7.5ml0.1M in the beaker of 50ml, slightlyUnder the condition stirring, add the chlorauric acid solution of 250 μ l0.01M, then add the 0.01M of freshly prepared 0 DEG CSodium borohydride solution 60 μ l, at the temperature of 25 DEG C of left and right, gentle agitation 2min, stand-by.
B. the preparation of growth-promoting media: get 50ml beaker several, to adding successively following solution in beaker: 0.1M'sCTAB solution 10ml, the chlorauric acid solution 425 μ l of 0.01M, the liquor argenti nitratis ophthalmicus 60 μ l of 0.01M, 80 μ l or100 μ l (silver nitrate of different amounts can generate the gold nanorods of different draw ratios), the ascorbic acid solution 67 μ l of 0.1M,Obtain growth-promoting media;
C. the preparation of gold nanorods: gold seeds liquid 105 μ l are joined in growth-promoting media, and whole process is all slightly being stirredMix and temperature is to carry out under the condition of 25 DEG C, continue to stir after adding medicine, after solution changes color, beaker is movedEnter temperature and be in the water bath with thermostatic control of 27-28 degree Celsius, the static processing of spending the night. After having reacted, obtain gold nanorods solution,Gold nanorods solution is moved in centrifuge tube, centrifugal front by solution heat treated, treat that the CTAB in solution is all moltenXie Hou, will put into centrifuge after medicine trim, and centrifugal condition is: 25 degrees Celsius, and 10000r/min, 20min, fromThe heart complete rear with suction pipe by supernatant sucking-off, precipitate with deionized water is dissolved again, repeats above centrifugal process 2 times,The gold nanorods of collection is resuspended in the deionized water of appropriate volume, the gold nanorods solution of collection is placed on to 4 DEG CRefrigerator in preserve, for after sign and react again.
2) porphyrin gold nanorods key connects
D. the preparation of porphyrin-cysteine solution: add the DMF solution of 25ml in the flask of 250ml, 50mgTo chloroethoxy phenyl porphyrin, 0.75g cysteine, after being uniformly mixed, adds 2～3 triethylamines,Add thermal response 24h, add appropriate saturated aqueous common salt and carrene to carry out separated product, will be dissolved with target and produceThe carrene of thing is purified by column chromatography, application 200 order silicagel columns, and carrene and methyl alcohol are by volumeThe solution mixing than 100:2.5, as eluent, is collected chromatographic band. Increase cysteine amount to 1g and 1.25g,Repeat said process, obtain porphyrin-cysteine solution of binding varying number cysteine.
E. the preparation of gold nanorods-cysteine-porphyrin: add the methyl alcohol of 15ml in the beaker of 50ml, 1mlThe gold nanorods solution that obtains of above-mentioned steps c and the binding varying number cysteine of the 1ml that obtains of steps dPorphyrin-cysteine solution, stirring at normal temperature 18-24h, reaction finishes rear centrifugal, outwells solution above, adds methyl alcoholAgain centrifugal, outwell solution above, then add DMF to disperse precipitation, ultrasonic processing disperses precipitation betterIn solution, obtain gold nanorods-cysteine-porphyrin compound.
3) preparation of Herceptin binding gold nanorods compound
Respectively gold nanorods-cysteine-the porphyrin of binding varying number cysteine is dispersed in to 0.005M'sIn CTAB solution, the concentration that makes gold nanorods-cysteine-porphyrin is 100nM, then uses glutaraldehyde cross-linkingPBS that method is 0.01M by gold nanorods-cysteine of 10ml-porphyrin Solution Dispersion in concentration (NaCl1.38M,KCl, 0.0027M, Tween-20 0.05% (v/v), pH7.4,5% (v/v) glutaraldehyde) in solution, normal temperaturePlace 1h (different time is set, finds optimum), centrifugal treating, precipitation is dispersed in the 0.01M preparing againPBS solution in, add the excessive Herceptin of 0.25ml-0.75ml, hatch 12h, centrifugal removing at 4 DEG CUnnecessary Herceptin, is dispersed in the gold nanorods-cysteine-porphyrin-Herceptin obtainingIn PBS (PH7.4) buffer solution, 4 DEG C of preservations of temperature, to obtain final product.
Fig. 1 is that the addition of liquor argenti nitratis ophthalmicus is 80 μ l, synthetic Jenner when the addition of cysteine is 0.75gThe image of the excellent porphyrin compound of rice under transmission electron microscope.
Embodiment 2 application of Herceptin binding gold nanorods compound in the diagnosis and treatment of HER2 positive breast cancer
1, application six orifice plates are cultivated HER2 high expressed BT474 breast cancer cell line, and every hole adds respectively 100ug/mlThe Herceptin binding gold nanorods compound (nitre of the binding varying number cysteine that embodiment 1 preparesAcid silver-colored solution addition be 80 μ l), 37 DEG C of 5%CO2Hatch 24 hours, by fluorescence microscope JennerThe excellent compound of rice is combined situation and fluorescent imaging with breast cancer cell surface receptor, result as shown in Figure 2, as seen withCysteine ratio increases (being from left to right respectively 0.75g, 1g and 1.25g), the stronger (arrow of porphyrin red fluorescenceShown in head), Cell binding Herceptin is also more, and target-oriented drug is better.
2, application 96 orifice plates are cultivated BT474 breast cancer cell, add respectively PBS liquid (control group), 25ug/mlThe bent appropriate pearl of Herceptin (Herceptin group), 100ug/ml gold nanorods (gold nanorods group), 100ug/ml-Porphyrin-cysteine (1.25g)-gold nanorods (fluorescent target is to gold nanorods group), every hole in triplicate, gives808nm near-infrared laser irradiates 5 minutes, and the dyeing of application Live/Deadviability/cytotoxicity kit, commentsThe photo-thermal therapy effect of the cytotoxicity of valency gold nanorods compound and gold nanorods mediation, result figure as shown in Figure 3,Arrow indication position is red fluorescence position, and visible fluorescence target gold nanorods complex group has stronger killing tumor cellsCytosis, compared with Herceptin group and gold nanorods group more remarkable effect, points out this Herceptin binding goldNanometer rods compound has good result for the treatment of to HER2 high expression tumour cell.
3, BT474 breast cancer cell is inoculated in to SCID mammary gland of mouse fat pad, sets up Breast Carcinoma in nude mice model,After tail vein injection Herceptin binding gold nanorods compound, observe, result as shown in Figure 4, visibleHerceptin binding gold nanorods compound can specific binding tumor focus, can indicate tumor focus by video picturePosition and infiltration degree, position and targeted therapy tumor focus to realize.
Claims (5)
1. a Herceptin binding gold nanorods compound, it is characterized in that by the effect of Au-S key,Gold nanorods and cysteine-porphyrin fluorescence molecule compound key are connected, then by the side of glutaraldehyde chemical crosslinkingMethod, gets gold nanorods-cysteine-porphyrin fluorescence molecule compound and medicine Herceptin key continuously, itsThe each several part being connected by next coming in order forms: gold nanorods, cysteine, porphyrin fluorescence molecule and bent appropriate pearlMonoclonal antibody.
2. Herceptin binding gold nanorods compound as claimed in claim 1, described in it is characterized in thatPorphyrin fluorescence molecule is to chloroethoxy phenyl porphyrin.
3. prepare a method for Herceptin binding gold nanorods compound claimed in claim 2, its spyLevy and be to comprise the following steps:
1) preparation of gold nanorods
A. the preparation of gold seeds liquid: to the CTAB solution that adds 7.5ml0.1M in beaker, in gentle agitationUnder condition, add the chlorauric acid solution of 250 μ l0.01M, then add the boron hydrogen of the 0.01M of freshly prepared 0 DEG CChange sodium solution 60 μ l, at the temperature of 22-28 DEG C, gentle agitation 1-5min, stand-by;
B. the preparation of growth-promoting media: to the CTAB solution that adds successively following solution: 0.1M in another beaker10ml, the chlorauric acid solution 425 μ l of 0.01M, the liquor argenti nitratis ophthalmicus 60 μ l-100 μ l of 0.01M, 0.1M's is anti-badHematic acid solution 67 μ l, obtain growth-promoting media after mixing;
C. the preparation of gold nanorods: gold seeds liquid 105 μ l are joined in growth-promoting media, and whole process is all slightly being stirredMix and temperature is to carry out under the condition of 22-28 DEG C, continue to stir after adding medicine, after solution changes color, will burnIt is in the water bath with thermostatic control of 27-28 degree Celsius that cup moves into temperature, the static processing of spending the night; After having reacted, obtain gold nanorodsSolution, moves into gold nanorods solution in centrifuge tube, centrifugally front solution is carried out to heat treated, treats in solutionAfter CTAB all dissolves, by putting into centrifuge after medicine trim, centrifugal, centrifugal complete supernatant is inhaled with suction pipe afterwardsGo out, precipitate with deionized water is dissolved again, repeats above centrifugal process 2 times, and the gold nanorods of collection is resuspended inIn the deionized water of appropriate volume, the gold nanorods solution of collection is placed in the refrigerator of 4 DEG C and preserves, for afterSign and react again;
2) porphyrin gold nanorods key connects
D. the preparation of porphyrin-cysteine solution: in flask, add the DMF solution of 25ml, 50mg to chloroetheneOxygen base phenyl porphyrin, 0.75g-1.25g cysteine, after being uniformly mixed, adds 2～3 triethylamines, heatingReaction 24h, adds saturated aqueous common salt and carrene to carry out product separation, will be dissolved with the dichloromethane of target substanceAlkane is purified by column chromatography, obtains porphyrin-cysteine solution;
E. the preparation of gold nanorods-cysteine-porphyrin: add successively methyl alcohol in beaker, above-mentioned steps c obtainsGold nanorods solution and porphyrin-cysteine solution of obtaining of steps d, stirring at normal temperature 18-24h, after reaction finishesCentrifugal, outwell solution above, add methyl alcohol again centrifugal, outwell solution above, then add DMF to disperse heavyForm sediment, ultrasonic processing is dispersed in solution precipitation better, obtains gold nanorods-cysteine-porphyrin compound;
3) preparation of Herceptin binding gold nanorods compound
First gold nanorods-cysteine-porphyrin compound is dispersed in the CTAB solution of 0.005M, makes JennerThe concentration of rice rod-cysteine-porphyrin compound is 100nM, then uses glutaraldehyde cross-linking method, by the Jenner of 10mlRice rod-cysteine-porphyrin complex solution is dispersed in the PBS solution that concentration is 0.01M, and normal temperature is placed0.5-2h, centrifugal treating, precipitation is dispersed in the PBS solution of the 0.01M preparing again, and it is excessive then to addHerceptin, hatch 12h at 4 DEG C, centrifugally remove unnecessary Herceptin, obtain gold nanorods-half GuangPropylhomoserin-porphyrin-Herceptin compound, is dispersed in the compound obtaining in the PBS solution of 0.01M temperature4 DEG C of preservations, to obtain final product.
4. method as claimed in claim 3, is characterized in that step 3) described in the PBS of 0.01M moltenLiquid is for containing 1.38MNaCl, 0.0027MKCl, 0.05% (v/v) Tween-20 and 5% (v/v) glutaraldehydeThe PBS solution of 0.01M, pH7.4.
5. the Herceptin binding gold nanorods compound described in claim 1 or 2 is in the preparation HER2 positiveApplication in breast cancer diagnosis and treatment reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511003574.5A CN105597098B (en) | 2015-12-28 | 2015-12-28 | A kind of bonded gold nanorods compound of Herceptin, preparation method and the application in HER2 positive breast cancer diagnosis and treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511003574.5A CN105597098B (en) | 2015-12-28 | 2015-12-28 | A kind of bonded gold nanorods compound of Herceptin, preparation method and the application in HER2 positive breast cancer diagnosis and treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105597098A true CN105597098A (en) | 2016-05-25 |
| CN105597098B CN105597098B (en) | 2019-05-31 |
Family
ID=55977803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511003574.5A Active CN105597098B (en) | 2015-12-28 | 2015-12-28 | A kind of bonded gold nanorods compound of Herceptin, preparation method and the application in HER2 positive breast cancer diagnosis and treatment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105597098B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106363192A (en) * | 2016-11-11 | 2017-02-01 | 南京东纳生物科技有限公司 | Continuous feeding parallel reaction device for preparation of gold nanorods and application thereof |
| CN108341908A (en) * | 2018-03-12 | 2018-07-31 | 江南大学 | A kind of shape memory high molecule material and preparation method thereof of feux rouges response |
| CN114081949A (en) * | 2021-12-08 | 2022-02-25 | 河南师范大学 | Porphyrin-functionalized-modified gold nano-material and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940892A (en) * | 2012-11-21 | 2013-02-27 | 哈尔滨工业大学 | Preparation method of targeting porphyrin fluorescent molecule and gold nanorod dyad |
-
2015
- 2015-12-28 CN CN201511003574.5A patent/CN105597098B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940892A (en) * | 2012-11-21 | 2013-02-27 | 哈尔滨工业大学 | Preparation method of targeting porphyrin fluorescent molecule and gold nanorod dyad |
Non-Patent Citations (2)
| Title |
|---|
| 苗凤真等: "曲妥珠单抗-纳米金探针的制备及对乳腺癌细胞的抑制作用", 《东南大学学报(医学版)》 * |
| 薄璇: "靶向性金纳米棒卟啉偶联物制备", 《哈尔滨工业大学硕士学位论文 万方数据库》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106363192A (en) * | 2016-11-11 | 2017-02-01 | 南京东纳生物科技有限公司 | Continuous feeding parallel reaction device for preparation of gold nanorods and application thereof |
| CN108341908A (en) * | 2018-03-12 | 2018-07-31 | 江南大学 | A kind of shape memory high molecule material and preparation method thereof of feux rouges response |
| CN114081949A (en) * | 2021-12-08 | 2022-02-25 | 河南师范大学 | Porphyrin-functionalized-modified gold nano-material and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105597098B (en) | 2019-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Progress in research on gold nanoparticles in cancer management | |
| Wang et al. | Recent progress in biomedical applications of persistent luminescence nanoparticles | |
| Jin et al. | Albumin-assisted synthesis of ultrasmall FeS2 nanodots for imaging-guided photothermal enhanced photodynamic therapy | |
| CN107501291B (en) | CD169 high-affinity anti-tumor compound and preparation method and application thereof | |
| CN108030919A (en) | The preparation of Human Serum Albumin Modified black phosphorus quantum dot and the application as sensitizer | |
| Cui et al. | Fluorescent silicon nanorods-based nanotheranostic agents for multimodal imaging-guided photothermal therapy | |
| CN105597098A (en) | Trastuzumab bond-linking gold nanorod compound, preparation method and application thereof in diagnosis and treatment of HER2 positive breast cancer | |
| CN110201191B (en) | Compound of functional protein and cyanine dye molecule and preparation method and application thereof | |
| CN106137970A (en) | A kind of composite nano materials with surface enhanced raman spectroscopy function and preparation method thereof | |
| Vo-Dinh et al. | Shining gold nanostars: From cancer diagnostics to photothermal treatment and immunotherapy | |
| CN109529034A (en) | 2nd area of near-infrared is conjugated nanoparticle and its preparation method and application | |
| Fekrazad et al. | Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells | |
| Sun et al. | PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer | |
| CN103273080A (en) | Nanometer golden flower and preparation method and application of nanometer golden flower | |
| Hu et al. | 808 nm near-infrared light-excited UCNPs@ mSiO2-Ce6-GPC3 nanocomposites for photodynamic therapy in liver cancer | |
| CN110893237A (en) | Application of copper-palladium alloy nanoparticles and autophagy inhibitor in preparation of medicine or kit for killing tumors based on photothermal effect | |
| CN106692991A (en) | Targeting magnetic nanoparticles having double-heating and imaging functions, and preparation method and use thereof | |
| Li et al. | Porous CuxCoyS supraparticles for in vivo telomerase imaging and reactive oxygen species generation | |
| CN103784978B (en) | A kind of albumen-dye composition and application thereof | |
| Zhou et al. | Recent advances of plasmonic gold nanoparticles in optical sensing and therapy | |
| Zhao et al. | Advances in Chiral Gold Nano‐Assemblies and Their Bioapplication Based on Optical Properties | |
| CN105999262B (en) | A kind of SiO that the nano-medicament carrier with active targeting tumour-bevacizumab mediates2@LDH, preparation method and application | |
| CN110184272A (en) | A kind of novel cyclic ternary aptamers and its synthetic method and application | |
| CN108578427B (en) | Folic acid modified gold nanoparticle, preparation method thereof and application of gold nanoparticle in preparation of radiosensitization treatment drug | |
| CN102940892B (en) | Preparation method of targeting porphyrin fluorescent molecule and gold nanorod dyad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |